Revashnee Naidoo

456 total citations
7 papers, 181 citations indexed

About

Revashnee Naidoo is a scholar working on Ophthalmology, Oncology and Immunology. According to data from OpenAlex, Revashnee Naidoo has authored 7 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Ophthalmology, 4 papers in Oncology and 4 papers in Immunology. Recurrent topics in Revashnee Naidoo's work include CAR-T cell therapy research (4 papers), Immunotherapy and Immune Responses (4 papers) and Ocular Oncology and Treatments (4 papers). Revashnee Naidoo is often cited by papers focused on CAR-T cell therapy research (4 papers), Immunotherapy and Immune Responses (4 papers) and Ocular Oncology and Treatments (4 papers). Revashnee Naidoo collaborates with scholars based in United States, Canada and United Kingdom. Revashnee Naidoo's co-authors include Emma Leach, Cheryl McAlpine, Pippa Corrie, Alan Anthoney, Omid Hamid, Avinash Gupta, Neil Steven, T.R. Jeffry Evans, Sion Lewis and Mario Sznol and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

Revashnee Naidoo

7 papers receiving 174 citations

Peers

Revashnee Naidoo

IMMUN

ONCOL

OPHTH

MB

RNMI

Cheryl McAlpine United States

Thomas Jouary France

Emma Sangalang United States

Rachel L. Davis United States

Jennifer Johnston United States

Andrew Furness United Kingdom

Joanna E. Brewer United Kingdom

Virpi Raivio Finland

Judith C. Kaiser United States

Alexandra Jacquet France

Cheryl McAlpine United States

Revashnee Naidoo

154 ×1.3

IMMUN

145 ×1.3

ONCOL

107 ×1.5

OPHTH

73 ×1.6

MB

56 ×1.4

RNMI

Citations per year, relative to Revashnee Naidoo Revashnee Naidoo (= 1×) peers Cheryl McAlpine

Countries citing papers authored by Revashnee Naidoo

Since Specialization

Citations

This map shows the geographic impact of Revashnee Naidoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Revashnee Naidoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Revashnee Naidoo more than expected).

Fields of papers citing papers by Revashnee Naidoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Revashnee Naidoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Revashnee Naidoo. The network helps show where Revashnee Naidoo may publish in the future.

Co-authorship network of co-authors of Revashnee Naidoo

This figure shows the co-authorship network connecting the top 25 collaborators of Revashnee Naidoo. A scholar is included among the top collaborators of Revashnee Naidoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Revashnee Naidoo. Revashnee Naidoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Dupont, Christopher D., Natalie Bath, Megan Butler, et al.. (2024). 368 Translational analyses reveal mechanisms of afami-cel’s anti-tumor activity in synovial sarcoma. Regular and Young Investigator Award Abstracts. A424–A424. 1 indexed citations

2.

Moore, Kathleen N., Adam Asch, Víctor Moreno, et al.. (2022). 2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer. 32. A472–A473. 1 indexed citations

3.

Leach, Emma, et al.. (2021). 868 Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels. Regular and Young Investigator Award Abstracts. A909–A909. 3 indexed citations

4.

Naidoo, Revashnee, Esra Güç, Emma Leach, et al.. (2021). 571 IL-2 combination with ImmTAC overcomes CD163+ TAM-like M2 macrophage inhibition of ImmTAC-mediated T cell killing of tumor cells. SHILAP Revista de lepidopterología. A600–A600. 3 indexed citations

5.

Hassel, Jessica C., Adel Benlahrech, Revashnee Naidoo, et al.. (2021). Abstract 1673: Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp. Cancer Research. 81(13_Supplement). 1673–1673. 3 indexed citations

6.

Butler, Marcus O., Revashnee Naidoo, Emma Leach, et al.. (2021). Abstract 517: Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells. Cancer Research. 81(13_Supplement). 517–517. 5 indexed citations

7.

Middleton, Mark R., Cheryl McAlpine, Victoria K. Woodcock, et al.. (2020). Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research. 26(22). 5869–5878. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact